

- 0.01/0.001 mg/kg/day
- 0.01 mg/kg/day
- NOAEL (NOAEL)
- 0.01 mg/kg/day (NOAEL) is the lowest dose at which no adverse effects were observed in the study.

0.01 mg/kg/day

I 0.01 mg/kg/day is the lowest dose at which no adverse effects were observed in the study.

1. NOAEL is the lowest dose at which no adverse effects were observed in the study.
2. MABEL (Minimal Adverse Biological Effect Level) is the lowest dose at which no adverse biological effects were observed in the study.

0.01 mg/kg/day is the lowest dose at which no adverse effects were observed in the study.

(CHMP) 2007 0.01 mg/kg/day is the lowest dose at which no adverse effects were observed in the study.¹

0.01 mg/kg/day

0.01 mg/kg/day is the lowest dose at which no adverse effects were observed in the study.

(CHMP) 2007 0.01 mg/kg/day is the lowest dose at which no adverse effects were observed in the study.

[glossary_exclude]


- European Medicines Agency (2023). *Scientific advice and protocol assistance*. Retrieved 18 February, 2024, from <https://www.ema.europa.eu/en/human-regulatory-overview/r>

research-and-development/scientific-advice-and-protocol-assistance#ema-inpage-item-63019

- International Conference on Harmonisation (2009). *Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2) Step 4*. Geneva: ICH. Retrieved 28 July, 2015, from https://database.ich.org/sites/default/files/M3_R2_Guideline.pdf
- National Institutes of Health (2015). *Principles and guidelines for reporting preclinical research*. Bethesda, MD: NIH. Retrieved 28 July, 2015, from <http://www.nih.gov/about/reporting-preclinical-research.htm>
- Committee for Medicinal Products for Human Use (2017). *EMA/CHMP/SWP/28367/07 Rev. 1 Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products*. London: European Medicines Agency. Retrieved 18 February, 2024, from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf[/glossary_exclude]

[glossary_exclude]□□□□

- Committee for Medicinal Products for Human Use (2017). *EMA/CHMP/SWP/28367/07 Rev. 1 Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products*. London: European Medicines Agency. Retrieved 18 February, 2024, from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf[/glossary_exclude]



A2-2.02.6-V1.2